Clinical Trial ResultsUpdated results from the NEXICART-1 trial show NXC-201 elicited a 94% overall response rate and a 75% complete response rate in 16 patients.
Market PotentialAnalysts forecast peak global NXC-201 sales of approximately $525M by 2035, given the initial clinical data and lack of FDA-approved agents for relapsed/refractory AL Amyloidosis.
Regulatory ApprovalThe FDA granted RMAT designation to NXC-201, which is being evaluated in the NEXICART-2 trial for the treatment of relapsed/refractory AL Amyloidosis.